Mykola Onyshchenko, MD
Medical Oncology · Duarte, CANPI 1821342775
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,643 of the $23,435 with a category attached, or 66.8%. 36 manufacturers reported payments, led by Sanofi at 38.7% of the total. Reporting peaked in 2023 at $11,383 and has fallen 98.7% since, to $149 in 2025.
Across 141 payments — averaging $166.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- Blueprint Medicines Corporation$3K
- Bayer$2K
- Regeneron$2K
- AstraZeneca$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $3K from 30 others
Across 59 payments — averaging $8765.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$122K
- Eli Lilly$119K
- Spectrum Pharmaceuticals Inc.$68K
- Daiichi Sankyo Inc.$63K
- Merck$39K
- Amgen$35K
- plus $71K from 3 others
What the payments were for
- Consulting fees$15,64367%
- Speaking & faculty fees$2,59911%
- Travel & lodging$1,2775%
- Food & beverage$3,91617%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 13 | $9,064 |
| Blueprint Medicines Corporation | 2 | $2,620 |
| Bayer | 5 | $2,277 |
| Regeneron | 1 | $2,100 |
| AstraZeneca(2 entities) | 20 | $2,065 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $2,017 |
| Eli Lilly | 4 | $521 |
| E.r. Squibb & Sons, L.L.C. | 15 | $226 |
| Amgen | 5 | $215 |
| Pinnacle Biologics, Inc | 3 | $204 |
| Galvanize Therapeutics, Inc | 1 | $198 |
| Pfizer | 8 | $176 |
| Eisai Inc. | 5 | $173 |
| Novartis | 4 | $162 |
| Lilly USA, LLC | 4 | $145 |
| Seagen Inc. | 2 | $143 |
| Clovis Oncology, Inc. | 1 | $125 |
| Genentech USA, Inc. | 5 | $97 |
| Adaptive Biotechnologies Corporation | 3 | $90 |
| Merck | 3 | $81 |
| Karyopharm Therapeutics Inc. | 3 | $81 |
| Mirati Therapeutics, Inc. | 3 | $80 |
| EMD Serono, Inc. | 3 | $79 |
| Stemline Therapeutics Inc. | 3 | $78 |
| Incyte Corporation | 3 | $66 |
| Bristol Myers Squibb | 2 | $60 |
| Johnson & Johnson | 2 | $55 |
| Exelixis Inc. | 2 | $46 |
| Daiichi Sankyo Inc. | 1 | $31 |
| Tesaro, Inc. | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| Foundation Medicine, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,435 in reported general payments places this provider in the 70th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 12 | $197,528 |
| Abiraterone Acetate | 25 | $81,569 |
| EliquisApixaban | 29 | $20,815 |
| Ondansetron OdtOndansetron | 36 | $762 |
| Prochlorperazine Maleate | 50 | $633 |
| Prednisone | 62 | $506 |
| Dexamethasone | 33 | $405 |
| Ondansetron Hcl | 30 | $330 |
| Tamoxifen Citrate | 12 | $270 |
| Letrozole | 15 | $245 |
| Gabapentin | 24 | $235 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $130 |
| Amlodipine Besylate | 17 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $2,065 | $197,52812 claims |
| PfizerEliquis | $176 | $20,81529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 379 medical oncology providers in California.
Other medical oncology in Duarte
- Daneng LiDuarte$467K
- Howard WestDuarte$426K
- Christine LovlyDuarte$362K
- Marwan FakihDuarte$203K
- Erminia MassarelliDuarte$176K
- Ravi SalgiaDuarte$142K
- Tanya DorffDuarte$136K
- Karen ReckampDuarte$132K
- Cy SteinDuarte$122K
- Joseph ChaoDuarte$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.